LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Liraglutide (Primary) ; Metformin (Primary) ; Sodium-glucose transporter 2 inhibitors (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms LIRA-ADD2SGLT2i
- Sponsors Novo Nordisk
- 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 06 Mar 2017 Status changed from not yet recruiting to recruiting.